Gene · 7130
Papers2,523
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
601 to 620 of 2,523
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hyaluronic Acid: Its Versatile Use in Ocular Drug Delivery with a Specific Focus on Hyaluronic Acid-Based Polyelectrolyte Complexes. | Pharmaceutics | 2022 | 35890371 | PubTator, text mining | PubMed |
| Research on Potential Network Markers and Signaling Pathways in Type 2 Diabetes Based on Conditional Cell-Specific Network. | Genes (Basel) | 2022 | 35885938 | PubTator, text mining | PubMed |
| Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential. | Stem Cell Res Ther | 2022 | 35883127 | PubTator, text mining | PubMed |
| Bone marrow mesenchymal stromal cells for diabetes therapy: touch, fuse, and fix? | Stem Cell Res Ther | 2022 | 35883121 | PubTator, text mining | PubMed |
| Chemokine Assay Matrix Defines the Potency of Human Bone Marrow Mesenchymal Stromal Cells. | Stem Cells Transl Med | 2022 | 35881077 | PubTator, text mining | PubMed |
| Using AI-Based Evolutionary Algorithms to Elucidate Adult Brain Tumor (Glioma) Etiology Associated with IDH1 for Therapeutic Target Identification. | Curr Issues Mol Biol | 2022 | 35877430 | PubTator, text mining | PubMed |
| Mesenchymal Stem Cell-Derived Antimicrobial Peptides as Potential Anti-Neoplastic Agents: New Insight into Anticancer Mechanisms of Stem Cells and Exosomes. | Front Cell Dev Biol | 2022 | 35874827 | PubTator, text mining | PubMed |
| Enhancing Mesenchymal Stromal Cell Potency: Inflammatory Licensing via Mechanotransduction. | Front Immunol | 2022 | 35874742 | PubTator, text mining | PubMed |
| Insight Into the Metabolic Adaptations of Electrically Pulse-Stimulated Human Myotubes Using Global Analysis of the Transcriptome and Proteome. | Front Physiol | 2022 | 35874526 | PubTator, text mining | PubMed |
| Single-Cell Transcriptome Analysis Reveals Mesenchymal Stem Cells in Cavernous Hemangioma. | Front Cell Dev Biol | 2022 | 35865633 | PubTator, text mining | PubMed |
| Possible Effect of the use of Mesenchymal Stromal Cells in the Treatment of Autism Spectrum Disorders: A Review. | Front Cell Dev Biol | 2022 | 35865626 | PubTator, text mining | PubMed |
| Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial. | Front Immunol | 2022 | 35860245 | PubTator, text mining | PubMed |
| Translating MSC Therapy in the Age of Obesity. | Front Immunol | 2022 | 35860241 | PubTator, text mining | PubMed |
| Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages. | Stem Cell Res Ther | 2022 | 35858897 | PubTator, text mining | PubMed |
| Mesenchymal stem cell treatment for hyperactive immune response in patients with COVID-19. | Immunotherapy | 2022 | 35855633 | PubTator, text mining | PubMed |
| TNFAIP6 Promotes Gastric Carcinoma Cell Invasion via Upregulating PTX3 and Activating the Wnt/β-Catenin Signaling Pathway. | Contrast Media Mol Imaging | 2022 | 35854776 | PubTator, text mining | PubMed |
| Immuno-Modulatory Effects of Intervertebral Disc Cells. | Front Cell Dev Biol | 2022 | 35846355 | PubTator, text mining | PubMed |
| Clinical progress in MSC-based therapies for the management of severe COVID-19. | Cytokine Growth Factor Rev | 2022 | 35843774 | PubTator, text mining | PubMed |
| Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects. | Cell Mol Biol Lett | 2022 | 35842587 | PubTator, text mining | PubMed |
| TSG-6 released from adipose stem cells-derived small extracellular vesicle protects against spinal cord ischemia reperfusion injury by inhibiting endoplasmic reticulum stress. | Stem Cell Res Ther | 2022 | 35831906 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7130/papers?page=31